IDEAYA Q2 2026 earnings: Darovasertib NDA advances with $1.24 billion in cash

IDEAYA Biosciences (NASDAQ: IDYA) reported Q2 2026 collaboration revenue of $8.9 million, up from $6.6 million in Q1 2026, while basic and diluted loss per share widened to $1.22 from $1.11. Higher clinical, personnel and commercial-preparation spending increased the net loss, but equity financing raised cash and marketable securities to approximately $1.24 billion as the company advanced darovasertib toward an NDA submission.

Core financial results

Collaboration revenue increased sequentially as IDEAYA recognized research and development services performed under its Servier licensing agreement for darovasertib. The remaining balance associated with these service obligations was $147.0 million at quarter-end and will be recognized over time as the work is completed.

Operating expenses rose to $131.1 million. R&D growth reflected higher clinical trial and personnel costs, while G&A increased partly because of hiring and preparations for a possible darovasertib launch.

The company provided sequential quarterly comparisons rather than year-over-year figures for the three-month period. Its six-month net loss was $211.0 million, compared with $149.7 million in the first half of 2025.

Business and pipeline performance

Darovasertib reached a registrational milestone

The Phase 2/3 OptimUM-02 trial met its primary endpoint in 313 first-line patients with HLA-A2:01-negative metastatic uveal melanoma. Blinded independent review showed median progression-free survival of 6.9 months for darovasertib plus crizotinib, versus 3.1 months for investigator’s choice of therapy. The hazard ratio was 0.42, with a p-value below 0.0001.

Investigator assessment produced a similar result: median progression-free survival was 6.7 months for the combination and 2.7 months for the control arm, with a hazard ratio of 0.36. IDEAYA said the combination also improved key secondary endpoints and had a manageable safety profile consistent with prior findings.

Overall survival data remained immature at the January 23, 2026 cutoff. The company expects to report a prespecified interim analysis in mid-2027. Meanwhile, the darovasertib NDA filing is underway through the FDA’s real-time oncology review program, with completion targeted for the second half of 2026.

IDEAYA also plans to present updated OptimUM-01 data from approximately 85 efficacy-evaluable HLA-A2:01-positive patients at ESMO in October 2026. Those results will be included in the NDA submission to support discussions about a potentially broader indication.

Other programs are approaching clinical updates

IDEAYA outlined several additional milestones for the remainder of 2026:

• Hengrui plans to present updated response, progression-free survival, safety and 12-month overall survival data for IDE849 from approximately 100 patients with small-cell lung cancer or neuroendocrine carcinomas at ESMO.
• IDEAYA expects the first data from its own global IDE849 Phase 1/2 trial in the second half of 2026 and is discussing a potential registrational trial design with the FDA.
• IDE892 monotherapy expansion has started in MTAP-deleted solid tumors. A combination cohort with IDE397 is also underway.
• A Phase 1 trial combining IDE892 with Roche’s pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic cancer is targeted to begin in the second half of 2026.
• Initial clinical data for the IDE034 bispecific antibody-drug conjugate are planned by the end of 2026 or early 2027.

IDEAYA is also evaluating capital allocation for the OptimUM-10 neoadjuvant study because of patient recruitment considerations. The company is assessing whether published OptimUM-09 data could support clinical guideline inclusion while allowing more investment in the DLL3 and MTAP/KRAS programs.

Equity financing outweighed cash burn as development spending rose

Cash, cash equivalents and marketable securities increased from $972.9 million at March 31 to approximately $1.24 billion at June 30 despite the quarterly net loss. The increase primarily came from $323.4 million in net proceeds from a June public offering and $33.1 million raised through the at-the-market program, partially offset by cash used in operations.

The public offering included 7,222,225 common shares and pre-funded warrants covering another 5,555,576 shares. This financing supports a longer development period, but it also increased the company’s share count and potential dilution while R&D and pre-commercial expenses were rising.

Guidance

IDEAYA maintained its existing cash runway outlook. The estimate is based on the current operating plan, making future spending decisions across the clinical portfolio an important variable.

Recent insider transactions

The supplied insider dataset showed 59,550 shares purchased across two transactions and 9,550 shares sold in one transaction during the latest six-month period, for net purchases of 50,000 shares. It reported total insider holdings of 1.95 million shares and a net purchase ratio of 2.60%; the detailed two-year record contained six entries rather than ten.

All six were reported as direct transactions. Because the list combines purchases and sales with stock awards and derivative conversions, the entries do not represent equivalent types of insider activity.

Risks investors need to watch

• Regulatory and clinical uncertainty: OptimUM-02 met its progression-free survival endpoint, but the NDA remains under preparation and review has not been completed. Overall survival data are also immature, with the next analysis expected in mid-2027.
• Higher development and launch-preparation costs: Both R&D and G&A expenses increased sequentially, widening the net loss. Continued trial expansion and pre-commercial work could keep spending elevated.
• Financing dilution: The June offering and at-the-market sales strengthened liquidity but added common shares and pre-funded warrants.
• Portfolio execution and capital allocation: IDEAYA is managing several clinical programs simultaneously and is reassessing investment in OptimUM-10. Delays, recruitment challenges or weaker clinical updates could alter development priorities.
• Revenue composition: Reported revenue consisted of Servier collaboration revenue recognized as R&D services were completed, rather than revenue from an approved commercial product.

Summary

IDEAYA’s Q2 2026 results centered on the positive OptimUM-02 outcome and progress toward a darovasertib NDA, while expanding clinical activity and commercial preparation pushed expenses and losses higher. Equity financing lifted available cash to approximately $1.24 billion and preserved runway guidance into 2030. The next major points to monitor are completion of the NDA submission, upcoming ESMO data, overall survival follow-up and the company’s capital allocation across its growing pipeline.